Moldwin Robert MD

Matthew J. Weiss, MD, FACS, is deputy physician-in-chief and director of the surgical oncology program at Northwell Cancer Institute. He's a board-certified surgeon specializing in pancreas and liver diseases.With a relentless work ethic and strong desire to help people, Dr. Weiss always knew he wanted to be a doctor. "I picked a field that allows me to tackle difficult problems and truly make an impact," he says.Dr. Weiss completed his residency in general surgery at Johns Hopkins Hospital and was dual fellowship trained in surgical oncology and hepatobiliary surgery at Memorial Sloan-Kettering Cancer Center. He was previously chief of hepatobiliary surgery at Johns Hopkins, where he was also director of the Pancreas and Liver Multidisciplinary Clinics and the complex general surgical oncology fellowship. He also performed the first robotic Whipple at Johns Hopkins University. Joining Northwell in 2019, Dr. Weiss created a multidisciplinary team of surgeons, medical and radiation oncologists, geneticists, and other specialists who collaborate to create unique treatment plans for patients across the health system. "Every cancer is different, and every patient is different," he says. "Communication among multiple providers is the best way to ensure you're treating the entire person, properly," he says. Dr. Weiss's team also works with scientists from Cold Spring Harbor Laboratory and Feinstein Institutes for Medical Research to develop and run groundbreaking clinical trials. An international leader in both liver and pancreas surgery, Dr. Weiss has authored over 250 peer-reviewed publications in the field, and he's currently a professor of surgery and oncology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. "Understanding both the science of the disease and the technological aspect of surgery is so important," he says. Dr. Weiss focuses on using cancer genetics to help find the right surgical approach for patients. When possible, he operates robotically using small incisions for faster healing, so patients don't have to wait as long to receive additional therapies that can improve outcomes. With recent advancements in the field, Dr. Weiss has been able to successfully perform high-risk surgeries that were turned down by other institutions. "Being a surgeon is a tremendous responsibility, and I don't take it lightly," he says. "I truly and deeply care about my patients and their families-I get to know them as people and am there throughout their entire journey. That's what I'm most proud of as a doctor."

Simon J. Hall, MD, joined Northwell Health in 2015. He is a urologist who specializes in the diagnosis and treatment of prostate, bladder and kidney cancers.After receiving his medical degree from the Columbia University Vagelos College of Physicians and Surgeons, Dr. Hall completed a residency in urology at Boston University School of Medicine and a fellowship in urologic oncology at Baylor College of Medicine."I was drawn to urology because of the variety of procedures and conditions involved, as well as the ability to take care of a patient from evaluation through medical or surgical treatment," he says. "Urologists also tend to have lifelong relationships with their patients, and that helps with the type of shared decision making that's necessary for care."Dr. Hall is especially drawn to providing clear, effective communication that advances patients' understanding of their diagnoses and treatment options. "Health literacy is about giving patients options that help guide them to the decision that fits them best," he says.Another passion is research and treatment that advances the field. Dr. Hall has focused on new therapies for prostate and bladder cancer, and has participated in numerous clinical trials, some of which generated data resulting in FDA approval of abiraterone (Zytiga) and enzulutamide (Xtandi).Currently, he's helping develop a prostate cancer risk calculator to allow urologists to better assess risk levels for cancer in patients with an elevated PSA and determine when a prostate MRI and biopsy is appropriate. Another innovation is a collaboration with Cold Spring Harbor Laboratory to develop biomarkers that identify those at higher risk for aggressive prostate cancer."The goal of these advances is always improved patient care," says Dr. Hall. "We're passionate about educating ourselves and evaluating how things are done so we can continue to advance our care."